Rebecca K West1, Ramit Ravona-Springer2,3, Abigail Livny2,4, Anthony Heymann5, Danit Shahar6, Derek Leroith7, Rachel Preiss2, Ruth Zukran2, Jeremy M Silverman1,8, Michal Schnaider-Beeri1,2. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Sheba Medical Center, The Joseph Sagol Neuroscience Center, Tel Aviv University, Tel Aviv, Israel. 3. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Sheba Medical Center, Diagnostic Imaging Department, affiliated to Sackler Facility of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Maccabi Healthcare Services, Tel Aviv, Israel. 6. The S. Daniel Abraham International Center for Health and Nutrition, Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel. 7. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 8. James J. Peters Veterans Affairs Medical Center, Bronx, NY.
Abstract
BACKGROUND: The association between caffeine and cognitive performance has not been tested in older individuals with type 2 diabetes (T2D). Its association with brain volume in T2D has been tested only in animals. METHODS: We examined the association of caffeine with cognitive function and brain volume in a sample of elderly diabetics participating in the Israel Diabetes and Cognitive Decline Study (n = 638) and the moderating effect of age on this association. In a subsample (n = 185) with magnetic resonance imaging, we also examined these associations with gray and white matter volumes (GM/WM). RESULTS: Using linear regression adjusting for cognition-related covariates, we found that higher caffeine intake was associated with better function in overall cognition (p = .018), attention/working memory (p = .002), executive functioning (p = .047), and semantic categorization (p = .026). Interaction analyses of caffeine intake with age were significant for semantic categorization (p = .025), and approached significance for overall cognition (p = .066). This association was driven by the older group (above-median) for whom the association of caffeine intake with semantic categorization (p = .001), attention/working memory (p = .007), executive functioning (p = .005), and overall cognition (p = .002) were significant. In the magnetic resonance imaging subsample, there was an interaction (p = .034) of caffeine intake with age for GM volume; in the older group, higher caffeine intake was associated with greater GM volume (β = .198, p = .033). CONCLUSIONS: Caffeine intake may have a beneficial role in cognitive functioning of elderly adults with T2D, which may be moderated by age. Greater GM volume may be a mechanism underlying the association of higher caffeine intake with better cognitive function.
BACKGROUND: The association between caffeine and cognitive performance has not been tested in older individuals with type 2 diabetes (T2D). Its association with brain volume in T2D has been tested only in animals. METHODS: We examined the association of caffeine with cognitive function and brain volume in a sample of elderly diabetics participating in the Israel Diabetes and Cognitive Decline Study (n = 638) and the moderating effect of age on this association. In a subsample (n = 185) with magnetic resonance imaging, we also examined these associations with gray and white matter volumes (GM/WM). RESULTS: Using linear regression adjusting for cognition-related covariates, we found that higher caffeine intake was associated with better function in overall cognition (p = .018), attention/working memory (p = .002), executive functioning (p = .047), and semantic categorization (p = .026). Interaction analyses of caffeine intake with age were significant for semantic categorization (p = .025), and approached significance for overall cognition (p = .066). This association was driven by the older group (above-median) for whom the association of caffeine intake with semantic categorization (p = .001), attention/working memory (p = .007), executive functioning (p = .005), and overall cognition (p = .002) were significant. In the magnetic resonance imaging subsample, there was an interaction (p = .034) of caffeine intake with age for GM volume; in the older group, higher caffeine intake was associated with greater GM volume (β = .198, p = .033). CONCLUSIONS:Caffeine intake may have a beneficial role in cognitive functioning of elderly adults with T2D, which may be moderated by age. Greater GM volume may be a mechanism underlying the association of higher caffeine intake with better cognitive function.
Authors: Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; James Schmeidler; Jeremy M Silverman; Mary Sano; Keren Koifmann; Rachel Preiss; Hadas Hoffman; Anthony Heymann; Michal Schnaider Beeri Journal: Int J Geriatr Psychiatry Date: 2013-08-08 Impact factor: 3.485
Authors: R Nick Bryan; Michel Bilello; Christos Davatzikos; Ronald M Lazar; Anne Murray; Karen Horowitz; James Lovato; Michael E Miller; Jeff Williamson; Lenore J Launer Journal: Radiology Date: 2014-04-29 Impact factor: 11.105
Authors: Mark A Espeland; Kirk Erickson; Rebecca H Neiberg; John M Jakicic; Thomas A Wadden; Rena R Wing; Lisa Desiderio; Guray Erus; Meng-Kang Hsieh; Christos Davatzikos; Barbara J Maschak-Carey; Paul J Laurienti; Kathryn Demos-McDermott; R Nick Bryan Journal: Diabetes Care Date: 2016-03-29 Impact factor: 19.112